1. Home
  2. BMR vs SKYE Comparison

BMR vs SKYE Comparison

Compare BMR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beamr Imaging Ltd.

BMR

Beamr Imaging Ltd.

HOLD

Current Price

$1.68

Market Cap

28.1M

Sector

Technology

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.72

Market Cap

29.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMR
SKYE
Founded
2009
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.1M
29.1M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
BMR
SKYE
Price
$1.68
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
88.0K
175.2K
Earning Date
02-26-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.20
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$0.57
52 Week High
$4.32
$5.75

Technical Indicators

Market Signals
Indicator
BMR
SKYE
Relative Strength Index (RSI) 43.17 43.27
Support Level $1.59 $0.71
Resistance Level $2.01 $0.83
Average True Range (ATR) 0.13 0.06
MACD -0.01 -0.01
Stochastic Oscillator 24.85 23.69

Price Performance

Historical Comparison
BMR
SKYE

About BMR Beamr Imaging Ltd.

Beamr Imaging Ltd provides content-adaptive video compression solutions for human viewing and machine vision. The company is trusted by technology companies such as NVIDIA and Amazon Web Services, and serves media companies including Netflix, Paramount, and JioHotstar. Using Emmy-winning patented technology, its solutions help deliver media content with high quality while reducing storage and delivery costs. Its customers include over-the-top content distributors, video streaming platforms, and Hollywood studios that use its products to store, distribute, and monetize video and images across devices. The company operates in the United States, Israel, and the rest of the world, with the United States generating maximum revenue.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: